Nagi Bioscience, a pioneering Swiss company pioneering cutting-edge laboratory technologies for the research of alternative model organisms, is proud to announce the launch of its exclusive Priority Access Program, providing access to five leading academic laboratories in the first-of-its-kind SydLab™ One platform. With a focus on research applications in oncology, neurodegenerative diseases, aging and age-related diseases and toxicology, SydLab™ One is to facilitate and accelerate the pioneering research projects of the five participating laboratories.
Starting facilities in September 2024, SydLab™ One will be used at each of the participating facilities where it will enable researchers to conduct high-throughput and precision experiments with unprecedented efficiency, reliability and reproducibility over a six-month period.
We are excited and honored to see our technology being adopted in a growing number of research projects and centers, including some of the most prestigious laboratories in the world.”
Matteo Cornaglia, PhD, CEO and co-founder of Nagi Bioscience
“The SydLab™ The platform is the culmination of over 10 years of interdisciplinary research and development, and it is truly exciting to now see its transformative potential in accelerating scientific discoveries in critical medical areas such as neurodegenerative and age-related diseases and beyond.”
The innovative SydLab™ A platform revolutionizes C. elegans experimentation, automating the entire process through a seamless integration of microfluidics, robotics, vision and artificial intelligence algorithms in a single benchtop device. The five participating laboratories have been widely recognized for their leadership C. elegans research and in their respective fields of application. They will be the first academic laboratories to integrate SydLab™ One in their research facilities. Their feedback will be instrumental in improving the platform for wider applications, helping to shape the future of automated, standardized and alternative biological research, drug candidate discovery and safety assessment.
SydLab™ One represents a leap forward in experimental biology, designed to address the challenges facing researchers working with C. elegansa model organism widely used to understand biological processes and has existed in academic and industrial R&D laboratories for more than sixty years. With the launch of the Priory Access Program, Nagi Bioscience is ushering in a new era of automation in C. elegans research. Providing five leading academic laboratories with access to the revolutionary SydLab™ A platform, Nagi Bioscience enables researchers to accelerate their work in critical areas such as oncology, neurodegenerative diseases, aging and toxicology. This program marks a pivotal step in advancing biological research, enhancing efficiency, accuracy and discovery capabilities at leading institutions.
